Radiopharm Theranostics Limited (RAD.AX)
| Previous close | 0.1200 |
| Open | 0.1200 |
| Bid | 0.1200 x N/A |
| Ask | 0.1250 x N/A |
| Day's range | 0.1200 - 0.1200 |
| 52-week range | 0.0850 - 0.2150 |
| Volume | |
| Avg. volume | 273,893 |
| Market cap | 40.718M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Radiopharm Theranostics Expands Supply Agreement With TerThera for Terbium-161 Isotope Use in Prostate Cancer
Agreement will supply Tb-161 for RAD 402, a potential next generation radiopharmaceutical for treatment of advanced prostate cancerSYDNEY, Australia, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce an expanded agreement with TerThera to supply the Company with Terbium-161 (Tb-161). The Tb-161 isotope will be linked to a proprietary monoc
- GlobeNewswire
Diamond Equity Research to Host Global Select Emerging Growth Invitational Virtual Investor Conference on June 13th, 2023
Presenting Companies to Host 25 Minute Presentations Followed by Question-and-Answer Session; Conference Open to all Retail and Institutional InvestorsNEW YORK, June 09, 2023 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its Global Select Spotlight Emerging Growth Invitational Investor Conference on June 13, 2023. The conference, which is open to all retail and institutional investors, will consist of a series of tw
- GlobeNewswire
Radiopharm Theranostics Receives FDA Orphan Drug Designation for Trivehexin (RAD 301) in Pancreatic Cancer
Trivehexin radiopharmaceuticals being developed for imaging and treatment of cancers expressing αvβ6-integrinPancreatic ductal adenocarcinoma is primary indication due to high unmet needPotential follow-on indications include non-small cell lung cancer, head and neck, and colorectal cancer SYDNEY, Australia, May 09, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic a
